Related Experiment Video
Updated: Oct 23, 2025

08:25
CMAP Scan MUNE MScan - A Novel Motor Unit Number Estimation MUNE Method
Published on: June 7, 2018
12.6K
Positive DAT-SCAN in SPG7: a case report mimicking possible MSA-C
Gabriele Bellini1, Eleonora Del Prete1,2, Elisa Unti2
1Department of Clinical and Experimental Medicine, Unit of Neurology, University of Pisa, Pisa, Italy.
BMC Neurology
|August 26, 2021
Summary
Spastic Paraplegia type 7 (SPG7) mutations can mimic Multiple System Atrophy type C (MSA-C) presentations. Genetic testing is crucial for atypical ataxia cases to ensure accurate diagnosis and guide potential future therapies.
Area of Science:
- Neuroscience
- Genetics
- Neurology
Background:
- Spastic Paraplegia type 7 (SPG7) is a common autosomal recessive hereditary spastic paraplegia (HSP) that can present with ataxia.
- Ataxia is a common symptom in various neurodegenerative disorders, including Multiple System Atrophy type C (MSA-C), an α-synucleinopathy.
- Dopamine Transporter imaging (DAT-SCAN) aids in differentiating MSA-C from other causes of ataxia.
Observation:
- A 70-year-old man presented with a 3-year history of gait difficulties, falls, and urinary urge incontinence.
- Neurological examination revealed ataxic gait, spasticity, limb ataxia, and mild hypokinesia.
- MRI showed cerebellar atrophy, and DAT-SCAN indicated bilateral nigro-striatal degeneration, suggesting possible MSA-C.
Findings:
- A genetic investigation revealed a mutation in the SPG7 gene.
- This is the first reported case of an SPG7 mutation presenting with nigrostriatal degeneration and clinical features mimicking MSA-C.
- The patient's atypical disease course, with preserved ambulation, prompted genetic investigation.
Implications:
- DAT-SCAN combined with clinical findings is valuable for distinguishing MSA from other adult-onset ataxias.
- Genetic investigation is essential for patients with atypical presentations to avoid misdiagnosis of MSA mimics.
- Accurate diagnosis is critical for prognosis and eligibility for future genetic therapies.

